Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

J Am Assoc Nurse Pract

Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M

doi: 10.1097/JXX.

Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Br J Dermatol.

Tsianakas A, Luger TA, Radin A

doi: 10.1111/bjd.15905.

Atopic Dermatitis

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA Dermatol

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K

doi: 10.1001/jamadermatol.2021.3023

Atopic Dermatitis

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

J Investig Allergol Clin Immunol.

Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E, Patruno C, Rongioletti F, Argenziano G, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Romita P, Di Bona D, Nisticò SP, Piras V, Calabrese G, Detoraki C, Carbonara M, Fabbrocini G

doi: 10.18176/jiaci.0641.

Atopic Dermatitis

Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS

J Am Acad Dermatol.

Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Bansal A, Kaur M, Rossi AB, Graham NMH, Patel N, Gadkari A

doi: 10.1016/j.jaad.2020.02.060.

Atopic Dermatitis

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Dermatol Ther (Heidelb).

Simpson EL

doi: 10.1007/s13555-017-0181-6.

Atopic Dermatitis

Dupilumab for Moderate-to-Severe Atopic Dermatitis

Skin Therapy Lett.

Vangipuram R, Tyring SK

Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B

doi: 10.1016/

Atopic Dermatitis

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

Am J Clin Dermatol.

Frampton JE, Blair HA

doi: 10.1007/s40257-018-0370-9.

Related content

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Dupilumab for Moderate-to-Severe Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis